Company intelligence / Profile preview

PharmaDiall LLC

Ownership: Private
Development stage: Phase 3

Overview

PharmaDiall developed Dimolegin, an original direct oral anticoagulant targeting factor Xa. In Phase 3 trials, Dimolegin demonstrated higher efficacy than Kleksan for indications similar to those recommended for COVID symptoms by the Russian Ministry of Health. In Phase 2 trials for prevention of venous thrombosis after knee replacement surgery, it showed superior efficacy compared to Fragmin with a low rate of significant bleeding events. The drug is positioned as a potential blockbuster due to its unique pharmacokinetics and once-daily dosing.

Therapeutic areas: Women's HealthCardiovascular
Modalities: Small molecules (biologically active chemicals)
Industry: Biotech

Drug pipeline

2 assets

dimolegin

1 more asset in the full pipeline.

Request access →

Beyond the preview

Go deeper on PharmaDiall LLC.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PharmaDiall LLC.

Explore the full profile